慢性乙型肝炎患者骨量减少/骨质疏松的危险因素及CT值的诊断价值

张静怡; 唐映梅; 李嘉琦; 王倩; 张宸瑞

doi:10.3969/j.issn.1001-5256.2022.05.013

慢性乙型肝炎患者骨量减少/骨质疏松的危险因素及CT值的诊断价值

DOI: 10.3969/j.issn.1001-5256.2022.05.013

a.
昆明医科大学第二附属医院消化内科，昆明 650000
b.
昆明医科大学第二附属医院放射科，昆明 650000

基金项目:

国家自然科学基金 (81660102);

国家自然科学基金 (81360072)

伦理学声明：本研究方案于2020年7月15日经由昆明医科大学第二附属医院伦理委员会批准，批号：审-PJ-2020-56。所有研究对象均知情同意。

利益冲突声明：本研究不存在研究者、伦理委员会成员、受试者监护人以及与公开研究成果有关的利益冲突。

作者贡献声明：张静怡负责课题设计，资料分析，拟定写作思路，撰写论文；李嘉琦、王倩、张宸瑞参与收集及分析数据；唐映梅负责指导撰写文章，修改论文并最后定稿。

详细信息

通信作者:
唐映梅，tangyingmei_med@kmmu.edu.cn

计量
- 文章访问数: 518
- HTML全文浏览量: 220
- PDF下载量: 48
- 被引次数: 0
出版历程
- 收稿日期: 2021-09-29
- 录用日期: 2021-11-01
- 出版日期: 2022-05-20

Risk factors for osteopenia/osteoporosis and the diagnostic value of CT value in patients with chronic hepatitis B

a.
Department of Gastroenterology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650000, China
b.
Department of Radiology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650000, China

Research funding:

National Natural Science Foundation of China (81660102);

National Natural Science Foundation of China (81360072)

More Information

Corresponding author: TANG Yingmei, tangyingmei_med@kmmu.edu.cn(ORCID: 0000-0002-0731-4198)

摘要

摘要: 目的评价在慢性乙型肝炎患者腹部CT中通过测量胸、腰椎CT值，诊断骨量减少/骨质疏松的诊断价值。分析慢性乙型肝炎患者发生骨量减少/骨质疏松的危险因素。方法回顾性纳入2019年1月—2020年12月在昆明医科大学第二附属医院就诊的慢性乙型肝炎患者112例，所有患者均完善了腹部CT检查，部分患者完善了双能X线骨密度测定(DXA)。测量T12椎体至L3椎体的CT值，分析每一椎体CT值与DXA检查基于L1~L4椎体测得的T-score值相比诊断骨量减少/骨质疏松的诊断价值。以椎体CT值为诊断标准，将纳入的慢性乙型肝炎患者分为骨量减少/骨质疏松组(n=55)与骨量正常组(n=57)，对比两组患者临床特征、生化指标，分析慢性乙型肝炎患者发生骨量减少/骨质疏松的危险因素。符合正态分布的计量资料两组间比较采用t检验；非正态分布的计量资料两组间比较采用Mann-Whitney U检验。计数资料组间比较采用χ²检验、Fisher确切检验、Bonferroni校正检验。相关性采用Pearson相关分析。多因素分析采用二元logistic回归分析。根据受试者工作特征曲线(ROC曲线)评估T12~L3椎体CT值诊断慢性乙型肝炎患者合并骨量减少/骨质疏松的诊断价值。一致性检验采用Kappa检验。结果分析46例在同次住院中完善了腹部CT和DXA检查患者的T12~L3椎体CT值，均分别与DXA检查结果中基于L1~L4椎体计算的T-score值有显著正相关性(r_T12=0.694，r_L1=0.661，r_L2=0.781，r_L3=0.685，P值均＜0.001)；经ROC曲线分析，L2椎体CT值ROC曲线下面积最大(0.863)，诊断骨量减少/骨质疏松具有较好准确性，与DXA检查结果具有较好一致性(K=0.648，P＜0.001)。分析112例慢性乙型肝炎患者临床特征、生化指标，提示高龄(比值比为1.108，95%CI：1.026~1.196，P=0.009)、合并肌少症(比值比为2.788，95%CI：1.009~7.707，P=0.048) 是骨量减少/骨质疏松发生的危险因素。结论慢性乙型肝炎患者常需定期复查腹部CT评估肝脏疾病进展情况，通过测量患者腹部CT图像中L2椎体CT值、L3椎体层面骨骼肌面积筛查是否存在骨量减少/骨质疏松、肌少症，及时干预，提高患者的预后、生活质量，具有较高临床意义。
- 乙型肝炎, 慢性 /
- 骨质疏松 /
- 肌减少症
Abstract: Objective To investigate the value of the CT values of thoracolumbar vertebrae measured by abdominal CT in the diagnosis of osteopenia/osteoporosis in patients with chronic hepatitis B, as well as the risk factors for osteopenia/osteoporosis in such patients. Methods A retrospective analysis was performed for 112 patients with chronic hepatitis B in the Second Affiliated Hospital of Kunming Medical University from January 2019 to December 2020. All patients underwent abdominal CT, and some patients underwent dual-energy X-ray absorptiometry (DXA). The CT values of T12 vertebral body to L3 vertebral body were measured, and the value of CT value of each vertebral body in the diagnosis of osteopenia/osteoporosis was analyzed in comparison with T-score of L1-L4 vertebral bodies measured by DXA. With the CT values of vertebral bodies as the diagnostic criteria, the patients with chronic hepatitis B enrolled were divided into osteopenia/osteoporosis group with 55 patients and normal bone mass group with 57 patients. Clinical features and biochemical parameters were compared between the two groups to analyze the risk factors for osteopenia/osteoporosis in patients with chronic hepatitis B. The t-test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups; the chi-square test, the Fisher's exact test, and the Bonferroni correction test were used for comparison of categorical data between groups. A Pearson correlation analysis was performed to investigate correlation, and a binary logistic regression analysis was used for multivariate analysis. The receiver operating characteristic (ROC) curve was used to investigate the value of CT values of T12-L3 vertebral bodies in the diagnosis of osteopenia/osteoporosis in patients with chronic hepatitis B. The Kappa test was used check consistency. Results A total of 46 patients who completed abdominal CT and DXA during the same time of hospitalization were analyzed, and their CT values of T12-L3 vertebral bodies were significantly positively correlated with the T-score values of L1-L4 vertebral bodies in DXA (r_T12=0.694, r_L1=0.661, r_L2=0.781, r_L3=0.685, all P < 0.001). The ROC curve analysis showed that the CT value of L2 vertebral body had the largest area under the ROC curve of 0.863 and showed a good accuracy in the diagnosis of osteopenia/osteoporosis, which was consistent with the results of DXA (K=0.648, P < 0.001). The clinical features and biochemical parameters of 112 patients with chronic hepatitis B were analyzed, and it was suggested that old age (odds ratio [OR]=1.108, 95% confidence interval [CI]: 1.026-1.196, P=0.009) and sarcopenia (OR=2.788, 95% CI: 1.009-7.707, P=0.048) were the risk factors for osteopenia/osteoporosis. Conclusion The patients with chronic hepatitis B often need regular abdominal CT to evaluate the progression of liver disease, and it is of high clinical significance to identify the presence or absence of osteopenia/osteoporosis and sarcopenia by measuring the CT value of L2 vertebral body and skeletal muscle area of L3 vertebrae plane, thereby giving timely intervention and improving patients' prognosis and quality of life.
- Hepatitis B, Chronic /
- Osteoporosis /
- Sarcopenia

HTML全文

图 1 利用3区法测量椎体CT值

注：a，椎体上终板的下一层；b，椎体中间层；c，下终板的上一层。

Figure 1. Measurement of vertebral body CT values using the 3-zone method

下载: 全尺寸图片幻灯片

图 2 在同一椎体上测量每一层面HU值

注：a，椎体上终板的下一层；b，椎体中间层；c，下终板的上一层。

Figure 2. Measurement of HU values at each level on the same vertebral body

下载: 全尺寸图片幻灯片

图 3 在L3层面测量骨骼肌组织面积

Figure 3. Measurement of skeletal muscle tissue area at the L3 level

下载: 全尺寸图片幻灯片

图 4 患者T12~L3椎体CT值诊断患者骨量减少/骨质疏松的ROC曲线

Figure 4. ROC curve of patient's T12-L3 vertebral body CT values for diagnosis of patient's osteopenia/osteoporosis

下载: 全尺寸图片幻灯片

表 1 患者T12~L3椎体CT值(cut-off值)诊断患者骨量减少/骨质疏松的ROC曲线分析

Table 1. ROC curve analysis of patients' T12-L3 vertebral body CT values (cut-off values) for diagnosis of patients with osteopenia/osteoporosis

椎体位置	AUC	灵敏度	特异度	约登指数	CT值(cut-off值，HU)
T12	0.836	0.714	0.906	0.620	140.0
L1	0.828	0.786	0.781	0.567	149.5
L2	0.863	0.786	0.875	0.661	137.0
L3	0.850	0.786	0.812	0.598	135.5

下载: 导出CSV

表 2 骨量减少/骨质疏松组、骨量正常组CHB患者临床特征比较

Table 2. Comparison of clinical characteristics of CHB patients in the reduced osteopenia /osteoporosis group and normal bone mass group

项目	骨量减少/骨质疏松组(n=55)	骨量正常组(n=57)	统计值	P值
年龄(岁)	57.36±5.13	53.47±6.59	t=-3.815	＜0.001
年龄≥60岁[例(%)]	17(30.9)	6(10.5)	χ²=7.126	0.008
性别[例(%)]			χ²=0.098	0.755
男	41(74.5)	41(71.9)
女	14(25.5)	16(28.1)
吸烟[例(%)]	35(63.6)	27(47.4)	χ²=2.997	0.083
饮酒[例(%)]	27(49.1)	30(35.1)	χ²=0.298	0.585
高血压[例(%)]	11(0.2)	7(12.3)	χ²=1.237	0.266
糖尿病[例(%)]	5(9.1)	12(21.1)	χ²=3.111	0.078
骨折病史[例(%)]	3(5.5)	1(1.8)	χ²=1.113	0.291
乙型肝炎病史(年)	6(1~20)	10(2~20)	Z=-0.459	0.646
抗病毒治疗[例(%)]	36(65.5)	36(63.2)	χ²=0.064	0.800
治疗疗程(月)	30(12~72)	24(4~48)	Z=-1.827	0.068
HBsAg阳性[例(%)]	54(98.2)	57(100)		0.491
HBeAg阳性[例(%)]	15(27.3)	21(36.8)	χ²=1.175	0.278
HBV DNA阳性[例(%)]	20(36.4)	28(49.1)	χ²=1.861	0.173
肝癌[例(%)]	6(10.9)	5(8.8)	χ²=0.104	0.704
肝硬化[例(%)]	47(85.5)	46(80.7)	χ²=0.449	0.503
腹水[例(%)]	30(54.5)	29(50.9)	χ²=0.151	0.697
脾大[例(%)]	41(74.5)	42(73.7)	χ²=0.011	0.917
食管胃底静脉曲张[例(%)]	42(76.4)	37(64.9)	χ²=1.766	0.184
Child-Pugh分级[例(%)]			χ²=0.408	0.815
A级	18(32.7)	19(33.3)
B级	25(45.5)	23(40.4)
C级	12(21.8)	15(26.3)
肌少症[例(%)]	19(34.5)	7(12.3)	χ²=7.784	0.005
超重[例(%)]	26(43.6)	21(29.8)	χ²=1.250	0.263
低体重[例(%)]	6(10.9)	2(3.5)	χ²=1.330	0.249

下载: 导出CSV

表 3 骨量减少/骨质疏松组、骨量正常组CHB患者生化指标比较

Table 3. Comparison of biochemical indices of CHB patients in the reduced osteopenia/osteoporosis group and normal bone mass group

项目	骨量减少/骨质疏松组(n=55)	骨量正常组(n=57)	统计值	P值
ALT(U/L)	33.50(24.75~64.00)	40.00(27.00~76.00)	Z=-1.28	0.200
AST(U/L)	44.00(32.50~61.25)	45.00(33.00~96.00)	Z=-0.57	0.566
ALP(U/L)	112.50(96.75~139.00)	114.00(88.0~161.00)	Z=-0.25	0.802
GGT(U/L)	53.50(25.50~99.50)	43.00(26.00~83.00)	Z=-0.72	0.474
TBil(μmol/L)	20.10(13.48~48.75)	22.40(15.70~38.65)	Z=-0.86	0.389
白蛋白(g/L)	33.37±7.05	34.76±7.92	t=1.045	0.298
前白蛋白(μg/L)	114(81~164)	101(69~180)	Z=-0.87	0.384
eGFR(ml·min^-1·1.73 m^-2)	97.00(86.75~104.00)	101.00(89.50~105.50)	Z=-1.57	0.116
TC(mmol/L)	3.66(3.02~4.15)	3.52(2.89~4.17)	Z=-0.47	0.641
TG(mmol/L)	0.93(0.71~1.23)	0.87(0.69~1.06)	Z=-0.69	0.489
PT(s)	14.60(13.60~17.00)	15.50(14.05~17.25)	Z=-0.96	0.335
APTT(s)	38.40(34.65~42.63)	39.50(36.40~43.55)	Z=-1.03	0.302
INR	1.16(1.06~1.40)	1.25(1.11~1.43)	Z=-1.05	0.293
血小板(×10⁹/L)	95.00(58.50~151.25)	86.00(49.50~134.50)	Z=-1.19	0.233

下载: 导出CSV

参考文献(24)

[1]	World Health Organization. Global Hepatitis Report, 2017[OR]. WHO 2017: Geneva. http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/.
[2]	LUXON BA. Bone disorders in chronic liver diseases[J]. Curr Gastroenterol Rep, 2011, 13(1): 40-48. DOI: 10.1007/s11894-010-0166-4.
[3]	QIU ML, XIE Y, WANG XH, et al. Practice guideline for patients with osteoporosis[J]. Chin J Intern Med, 2020, 5(12): 953-959. DOI: 10.3760/cma.j.cn112138-20200904-00792. 邱敏丽, 谢雅, 王晓红, 等. 骨质疏松症患者实践指南[J]. 中华内科学杂志, 2020, 5(12): 953-959. DOI: 10.3760/cma.j.cn112138-20200904-00792.
[4]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. Chin J Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[5]	HAYASHI M, ABE K, FUJITA M, et al. Association between sarcopenia and osteoporosis in chronic liver disease[J]. Hepatol Res, 2018, 48(11): 893-904. DOI: 10.1111/hepr.13192.
[6]	SCHREIBER JJ, ANDERSON PA, ROSAS HG, et al. Hounsfield units for assessing bone mineral density and strength: a tool for osteoporosis management[J]. J Bone Joint Surg Am, 2011, 93(11): 1057-1063. DOI: 10.2106/JBJS.J.00160.
[7]	NISHIKAWA H, SHIRAKI M, HIRAMATSU A, et al. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria[J]. Hepatol Res, 2016, 46(10): 951-963. DOI: 10.1111/hepr.12774.
[8]	WANG YF, SUN MX, XUE H, et al. Understanding the China Blue Paper on Obesity Prevention and Control and policy implications and recommendations for obesity prevention and control in China[J]. Chin J Rrev Med, 2019, 53(9): 875-884. DOI: 10.3760/cma.j.issn.0253-9624.2019.09.003. 王友发, 孙明晓, 薛宏, 等. 《中国肥胖预防和控制蓝皮书》解读及中国肥胖预防控制措施建议[J]. 中华预防医学杂志, 2019, 53(9): 875-884. DOI: 10.3760/cma.j.issn.0253-9624.2019.09.003.
[9]	BYRNE DD, NEWCOMB CW, CARBONARI DM, et al. Risk of hip fracture associated with untreated and treated chronic hepatitis B virus infection[J]. J Hepatol, 2014, 61(2): 210-218. DOI: 10.1016/j.jhep.2014.04.001.
[10]	REID IR. Targeting sclerostin in postmenopausal osteoporosis: Focus on romosozumab and blosozumab[J]. BioDrugs, 2017, 31(4): 289-297. DOI: 10.1007/s40259-017-0229-2.
[11]	FORESTA C, SCHIPILLITI M, CIARLEGLIO FA, et al. Male hypogonadism in cirrhosis and after liver transplantation[J]. J Endocrinol Invest, 2008, 31(5): 470-478. DOI: 10.1007/BF03346393.
[12]	ZHU LJ, KE JT, LI M, et al. Studies related to the clearance of fibroblast growth factor 23 in patients with chronic renal failure by different modes of blood purification[J]. Chin J Integ Trad Western Nephrol, 2014, 15(6): 514-517. https://www.cnki.com.cn/Article/CJFDTOTAL-JXSB201406019.htm 朱丽娟, 柯剑婷, 李宓, 等. 不同血液净化模式对慢性肾衰竭患者成纤维细胞生长因子23清除的相关研究[J]. 中国中西医结合肾病杂志, 2014, 15(6): 514-517. https://www.cnki.com.cn/Article/CJFDTOTAL-JXSB201406019.htm
[13]	ZHANG ZL, WEI Z. Advances in clinical studies of adefovir-induced renal tubular damage and osteochondrosis[J]. Chin J Intern Med, 2018, 57(12): 935-937. DOI: 10.3760/cma.j.issn.0578-1426.2018.12.013. 章振林, 魏哲. 阿德福韦酯引起肾小管损害和骨软化临床研究进展[J]. 中华内科杂志, 2018, 57(12): 935-937. DOI: 10.3760/cma.j.issn.0578-1426.2018.12.013.
[14]	SMITH AD. Screening of bone density at CT: An overlooked opportunity[J]. Radiology, 2019, 291(2): 368-369. DOI: 10.1148/radiol.2019190434.
[15]	BAO J, ZOU D, LI WS. Research progress on lumbar CT attenuation value in assessing bone mineral density of patients with lumbar degenerative diseases[J]. Chin J Spine and Spinal Core, 2020, 30(8): 745-750. DOI: 10.3969/j.issn.1004-406X.2020.08.12. 包洁, 邹达, 李危石. 椎体CT值评估腰椎退变患者骨密度的研究进展[J]. 中国脊柱脊髓杂志, 2020, 30(8): 745-750. DOI: 10.3969/j.issn.1004-406X.2020.08.12.
[16]	LEE S, CHUNG CK, OH SH, et al. Correlation between bone mineral density measured by dual-energy X-Ray absorptiometry and hounsfield units measured by diagnostic CT in lumbar spine[J]. J Korean Neurosurg Soc, 2013, 54(5): 384-389. DOI: 10.3340/jkns.2013.54.5.384.
[17]	HAO RR, WANG H, WANG HY, et al. Analysis of risk factors for senile sarcopenia and its relationship with NAFLD[J]. J Clin Exp Med, 2020, 19(15): 1588-1591. DOI: 10.3969/j.issn.1671-4695.2020.15.006. 郝瑞瑞, 王欢, 王海燕, 等. 老年肌少症的危险因素分析及与NAFLD的关系研究[J]. 临床和实验医学杂志, 2020, 19(15): 1588-1591. DOI: 10.3969/j.issn.1671-4695.2020.15.006.
[18]	CHEN LR, YANG ZY. Research progress of intervention therapy for sarcopenia and understanding of traditional Chinese medicine[J]. Chin J Gerontol, 2021, 41(15): 3389-3392. DOI: 10.3969/j.issn.1005-9202.2021.15.063. 陈丽如, 杨子艳. 肌少症的干预治疗研究进展及中医学认识[J]. 中国老年学杂志, 2021, 41(15): 3389-3392. DOI: 10.3969/j.issn.1005-9202.2021.15.063.
[19]	HOU JC, ZHANG YM. Progress of skeletal muscle mass evaluation, diagnosis and treatment of sarcopenia in patients with liver disease[J]. Chin J Hepatobiliary Surg, 2020, 26(11): 873-877. DOI: 10.3760/cma.j.cn113884-20200304-00112. 侯建存, 张雅敏. 肝病患者肌肉减少症骨骼肌测量及诊治研究进展[J]. 中华肝胆外科杂志, 2020, 26(11): 873-877. DOI: 10.3760/cma.j.cn113884-20200304-00112.
[20]	CAREY EJ, LAI JC, SONNENDAY C, et al. A north american expert opinion statement on sarcopenia in liver transplantation[J]. Hepatology, 2019, 70(5): 1816-1829. DOI: 10.1002/hep.30828.
[21]	GOLSE N, BUCUR PO, CIACIO O, et al. A new definition of sarcopenia in patients with cirrhosis undergoing liver transplantation[J]. Liver Transpl, 2017, 23(2): 143-154. DOI: 10.1002/lt.24671.
[22]	CHEN JC, ZHU GT, LIU HW, et al. Common pathogenesis of "sarco-osteopenia"[J]. Chin J Osteoporosis Bone Miner Res, 2020, 13(1): 95-102. DOI: 10.3969/j.issn.1674-2591.2020.01.015. 陈锦成, 朱国涛, 刘洪文, 等. "肌少-骨质疏松症"的共同发病机制[J]. 中华骨质疏松和骨矿盐疾病杂志, 2020, 13(1): 95-102. DOI: 10.3969/j.issn.1674-2591.2020.01.015.
[23]	FU SW. Clinical study of bone metabolic and biochemical indexes and osteoporosis in patients with liver cirrhosis or liver cancer[J]. Chin J Osteoporos, 2013, 19(11): 1177-1179. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZS201311015.htm 付士武. 肝硬化、肝癌患者骨代谢生化指标与骨质疏松的临床研究[J]. 中国骨质疏松杂志, 2013, 19(11): 1177-1179. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZS201311015.htm
[24]	CHEN CH, LIN CL, KAO CH. Association between chronic hepatitis B virus infection and risk of osteoporosis: A nationwide population-based study[J]. Medicine (Baltimore), 2015, 94(50): e2276. DOI: 10.1097/MD.0000000000002276.